Nature communications · 2020
Disruption of the tumour-associated EMP3 enhances erythroid proliferation and causes the MAM-negative phenotype.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thornton Nicole, Karamatic Crew Vanja, Tilley Louise, Green Carole A, Tay Chwen Ling, Griffiths Rebecca E, Singleton Belinda K, Spring Frances, Walser Piers, Alattar Abdul Ghani, Jones Benjamin, Laundy Rosalind, Storry Jill R, Möller Mattias, Wall Lorna, Charlewood Richard, Westhoff Connie M, Lomas-Francis Christine, Yahalom Vered, Feick Ute, Seltsam Axel, Mayer Beate, Olsson Martin L, Anstee David J
Аннотация
The clinically important MAM blood group antigen is present on haematopoietic cells of all humans except rare MAM-negative individuals. Its molecular basis is unknown. By whole-exome sequencing we identify EMP3, encoding epithelial membrane protein 3 (EMP3), as a candidate gene, then demonstrate inactivating mutations in ten known MAM-negative individuals. We show that EMP3, a purported tumour suppressor in various solid tumours, is expressed in erythroid cells. Disruption of EMP3 by CRISPR/Cas9 gene editing in an immortalised human erythroid cell line (BEL-A2) abolishes MAM expression. We find EMP3 to associate with, and stabilise, CD44 in the plasma membrane. Furthermore, cultured erythroid progenitor cells from MAM-negative individuals show markedly increased proliferation and higher reticulocyte yields, suggesting an important regulatory role for EMP3 in erythropoiesis and control of cell production. Our data establish MAM as a new blood group system and demonstrate an interaction of EMP3 with the cell surface signalling molecule CD44.